Laboratory and Clinical studies on T-cells recognizing NSCLC

T 细胞识别 NSCLC 的实验室和临床研究

• 批准号: 9344018
• 负责人: James C Yang
• 金额: $ 45.61万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9344018
• 关键词: Antibodies; Antigens; Back; Cancer Etiology; Cells; Cessation of life; Clinical Protocols; Clinical Research; Development; Disease; Human; Immune response; Immunotherapy; Laboratory Study; Lymphocyte; Malignant Neoplasms; Malignant neoplasm of lung; Methods; Mutate; Mutation; Non-Small-Cell Lung Carcinoma; Operative Surgical Procedures; Patients; Proteins; Science; Staging; T-Lymphocyte; Therapeutic; genome sequencing; patient subsets; tumor

We have begun a clinical protocol to determine if resident lymphocytes in non-small cell lung cancer are reactive with tumor specific mutated "neo-antigens" and if so, whether they can be therapeutic if given patients using methods recently developed in the Surgery Branch (Tran et al, Science 2014). We are studying ways to sequence the genome of a patient's lung cancer, identify all mutated proteins, redisplay them effectively to the T-cells in their tumors and search for T-cells that can react to these mutated neo-antigens. We then wish to develop ways to isolate or enrich them, grow them and readminister them for therapy.

我们已经开始制定临床方案，以确定非小细胞肺癌中的居民淋巴细胞是否与肿瘤特异性突变的“新抗原”反应性，如果是这样，如果使用最近在手术分支中开发的方法给予患者，是否可以治疗（Tran等，Science，Science 2014）。我们正在研究对患者肺癌的基因组进行测序，鉴定所有突变蛋白的基因组，有效地重新发挥其肿瘤中的T细胞，并寻找可以对这些突变的新抗原反应的T细胞。然后，我们希望开发方法来隔离或丰富它们，成长它们并将其重新介绍以进行治疗。